Neonatal Intensive Care Unit, Perth Children's Hospital, Perth, WA, Australia.
Neonatal Intensive Care Unit, King Edward Memorial Hospital, Perth, WA, Australia.
Pediatr Res. 2023 Dec;94(6):1887-1905. doi: 10.1038/s41390-023-02716-w. Epub 2023 Jul 17.
Bifidobacterium infantis has special abilities to utilise human milk oligosaccharides. Hence we hypothesised that probiotic supplements containing B. infantis may confer greater benefits to preterm infants than probiotic supplements without B. infantis.
A systematic review with meta-analysis was conducted according to standard guidelines. We selected RCTs evaluating probiotics compared to placebo or no treatment in preterm and/or low birth weight infants. Probiotic effects on Necrotizing Enterocolitis (NEC), Late Onset Sepsis (LOS) and Mortality were analysed separately for RCTs in which the supplemented probiotic product contained B. infantis and those that did not contain B. infantis.
67 RCTs were included (n = 14,606), of which 16 used probiotics containing B. infantis (Subgroup A) and 51 RCTs did not (Subgroup B) Meta-analysis of all RCTs indicated that probiotics reduced the risk of NEC, LOS, and mortality. The subgroup meta-analysis demonstrated greater reduction in the incidence of NEC in subgroup A than subgroup B [(relative risk in subgroup A: 0.38; 95% CI, 0.27-0.55) versus (0.67; 95% CI, 0.55-0.81) in subgroup B; p value for subgroup difference: 0.01].
These results provide indirect evidence that probiotic supplements that include B. infantis may be more beneficial for preterm infants. Well-designed RCTs are necessary to confirm these findings.
Evidence is emerging that beneficial effects of probiotics are species and strain specific. This systematic review analyses if B. infantis supplementation provides an advantage to preterm infants. This is the first systematic review evaluating the effects of probiotics containing B. infantis in preterm infants. The results of this systematic review provides indirect evidence that probiotics that include B. infantis may be more beneficial for preterm infants. These results will help in guiding future research and clinical practice for using B. infantis as a probiotic in preterm infants.
婴儿双歧杆菌具有特殊的利用人乳寡糖的能力。因此,我们假设含有婴儿双歧杆菌的益生菌补充剂可能比不含婴儿双歧杆菌的益生菌补充剂对早产儿有更大的益处。
根据标准指南进行系统评价和荟萃分析。我们选择了比较益生菌与安慰剂或无治疗在早产儿和/或低出生体重儿的 RCT。对于补充益生菌产品含有婴儿双歧杆菌和不含有婴儿双歧杆菌的 RCT,分别分析益生菌对坏死性小肠结肠炎(NEC)、晚发性败血症(LOS)和死亡率的影响。
纳入了 67 项 RCT(n=14606),其中 16 项使用了含有婴儿双歧杆菌的益生菌(亚组 A),51 项 RCT 没有(亚组 B)。所有 RCT 的荟萃分析表明,益生菌降低了 NEC、LOS 和死亡率的风险。亚组荟萃分析表明,亚组 A 中 NEC 的发生率降低幅度大于亚组 B[亚组 A 的相对风险:0.38;95%CI,0.27-0.55]vs[亚组 B:0.67;95%CI,0.55-0.81];亚组差异的 p 值:0.01]。
这些结果提供了间接证据,表明含有婴儿双歧杆菌的益生菌补充剂可能对早产儿更有益。需要进行精心设计的 RCT 来证实这些发现。
有证据表明益生菌的有益作用是特定于物种和菌株的。本系统评价分析了婴儿双歧杆菌的补充是否为早产儿提供了优势。这是第一个评估含有婴儿双歧杆菌的益生菌对早产儿影响的系统评价。本系统评价的结果提供了间接证据,表明含有婴儿双歧杆菌的益生菌可能对早产儿更有益。这些结果将有助于指导未来使用婴儿双歧杆菌作为早产儿益生菌的研究和临床实践。